What is Ons Bio?
Ons Bio operates at the intersection of cutting-edge biotechnology and industrial research, specializing in 3D bioprinting and the development of proprietary bioinks. The company provides a comprehensive suite of life science research products designed to enhance the efficiency and accuracy of laboratory workflows. Beyond hardware, Ons Bio offers sophisticated analytical services, including proteomics, metabolomics, glycomics, and bioinformatics. By integrating lab equipment leasing with strategic business solutions for manufacturers entering the US market, the company serves a diverse clientele spanning pharmaceutical, biotechnology, agricultural, and academic sectors. Their market position is defined by a commitment to providing high-quality, accessible solutions that bridge the gap between theoretical research and practical application.
How much funding has Ons Bio raised?
Ons Bio has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
Key Investors in Ons Bio
PPP
Public-Private Partnership
What's next for Ons Bio?
With the recent infusion of capital, Ons Bio is poised to scale its infrastructure and expand its service offerings to meet the growing demand for high-throughput bioprinting solutions. The strategic focus will likely shift toward enhancing their bioinformatics platform and broadening their reach within the global life science supply chain. As the company transitions through this significant growth phase, the emphasis will remain on optimizing research outcomes for their partners in the pharmaceutical and biotechnology industries. By maintaining a focus on innovation and operational excellence, Ons Bio is set to capitalize on the increasing integration of automated research tools in modern laboratory environments, ensuring long-term sustainability and market leadership.
See full Ons Bio company page
